FindTrial
Sign In

Guardant Reveal

DIAGNOSTIC_TEST2 trials

Sponsors

Guardant Health, Inc., SWOG Cancer Research Network

Conditions

Bladder CarcinomaColon AdenocarcinomaCutaneous MelanomaEndometrial CarcinomaEpithelial Ovarian CarcinomaEsophageal CarcinomaFallopian Tube CarcinomaGastric Adenocarcinoma

Phase 3

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
Not yet recruitingNCT07802626
SWOG Cancer Research NetworkHR Positive/HER-2 Negative Breast Cancer
Start: 2026-10-30End: 2035-10-30Target: 1084Updated: 2026-09-03

Unknown Phase

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingNCT05059444
Guardant Health, Inc.Bladder Carcinoma, Colon Adenocarcinoma, Cutaneous Melanoma +14
Start: 2021-09-07End: 2030-08-01Target: 2285Updated: 2026-09-14